Navigation Links
An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes

ttings. There are no contraindications for JANUVIA.

Sitagliptin is also a component of JANUMET(TM) (sitagliptin/metformin HCl), the first and only tablet combining a DPP-4 inhibitor and metformin for the treatment of type 2 diabetes. JANUMET is indicated, as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes who are not adequately controlled on metformin or sitagliptin alone or in patients already being treated with the combination of sitagliptin and metformin. Consistent with the labeling for metformin alone, JANUMET is contraindicated in patients with renal disease, renal dysfunction, or abnormal creatinine clearance; and acute or chronic metabolic acidosis, including diabetic ketoacidosis. JANUMET should not be used in patients with type 1 diabetes. Consistent with the labeling for metformin alone, the labeling for JANUMET contains a boxed warning for lactic acidosis, a rare, but serious, metabolic complication that can occur due to metformin accumulation during treatment.

Investigational use of JANUVIA and metformin as initial combination therapy led to improvement in markers of beta cell function in patients with type 2 diabetes (0533-P; Study #036)

In this investigational study, the effects of JANUVIA and metformin on beta cell function were examined in patients with type 2 diabetes who participated in a 24-week, placebo-controlled study in which 1,091 patients were randomized to one of six treatments: JANUVIA 50 mg/metformin 1000 mg twice daily (n=182); JANUVIA 50 mg/metformin 500 mg twice daily (n=190); metformin 1000 mg twice daily (n=182); metformin 500 mg twice daily (n=182); JANUVIA 100 mg once-daily (n=179); or placebo (n=176). Of these, a subset of 500 patients underwent frequently sampled meal tolerance tests. Beta cell function was measured using a computer model based evaluation. Parameters of beta cell function from this model allowed for the estimation of the insulin secretion r
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
3. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
4. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
5. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
6. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Bedrocan Cannabis Corp., ... independent members to its Board of Directors, enhancing ... of the company, a leading licensed producer of ... Internationally, Bedrocan has 13 years, experience in producing ... seven countries, including Canada. As ...
(Date:8/21/2014)...  Cyberonics, Inc. (NASDAQ: CYBX ) today announced ... Quarterly highlights 1   Operating results for ... quarter of fiscal 2014, and other achievements, include: , ... 6.8%; , Strong international net sales of $13.2 million, ... , U.S. net product sales reached a new high of ...
(Date:8/21/2014)... 21, 2014 Asterias Biotherapeutics, Inc. (OTCBB: ASTY), ... regenerative medicine, announced today the appointments of Andrew ("Andy") ... expanded Board of Directors. With these additions, the Asterias ... whom are independent. Andy Arno , ... growth companies. He is currently Managing Director of Emerging ...
Breaking Medicine Technology:Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4
... 9, 2011 UCL Business (UCLB), a wholly owned ... Dickinson and Company), a leading global medical technology company, ... detection of ovarian and breast cancers to ultimately enable ... demonstrates how UCL and the Institute for Women,s Health ...
... Feb. 9, 2011 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... an investor briefing on Sunday, February 13 from 9 ... briefing, principal investigators from the VEGF Trap-Eye clinical studies ... Angiogenesis, Exudation and Degeneration 2011 meeting being held in ...
Cached Medicine Technology:BD and UCL Business Reach Exclusive License Agreement to Advance Development of New Diagnostic Tests for Ovarian and Breast Cancers 2BD and UCL Business Reach Exclusive License Agreement to Advance Development of New Diagnostic Tests for Ovarian and Breast Cancers 3BD and UCL Business Reach Exclusive License Agreement to Advance Development of New Diagnostic Tests for Ovarian and Breast Cancers 4Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET 2Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET 3Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET 4Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET 5
(Date:8/21/2014)... 21, 2014 According to a new ... Device System Market- Global Industry Analysis, Size, Share, Growth, ... device market was valued at USD 1,531.2 million in ... of 22.8% from 2013 to 2019, to reach an ... Globally, the microfluidic device market is witnessing significant growth ...
(Date:8/21/2014)... New York, New York (PRWEB) August 21, 2014 ... the Medical Cannabis Network that a company located in ... to be the only marijuana patient verification ... like to welcome this new entity to our growing ... due to our belief that these claims are inaccurate. ...
(Date:8/21/2014)... Aug. 21, 2014 (HealthDay News) -- Researchers report that ... cellular connections -- in their brains compared with typical ... possible to reduce the number of extra synapses through ... brain where brain cells (neurons) connect and communicate with ... impact on how the brain functions, theorized neuroscientists at ...
(Date:8/21/2014)... United Benefit Advisors (UBA), the nation’s ... to announce Trinity Benefit Advisors as its newest ... Benefit Advisors is a full service firm that ... Their consultative approach is comprised of four components: ... monitoring. Their dedication to effective results and absolute ...
(Date:8/21/2014)... 2014 The report "Indoor ... Hybrid), Maps and Navigation, Location based analytics, ... - Worldwide Market Forecasts and Analysis (2014 ... location market into various sub-segments with an ... report also identifies the factors driving this ...
Breaking Medicine News(10 mins):Health News:Global Microfluidic Device System Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Global Microfluidic Device System Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:MarijuanaDoctors.com Responds to Massachusetts Company's Claim 2Health News:Kids With Autism Have Extra Brain Connections, Study Says 2Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 2Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 3Health News:Indoor Location Market Worth $3.9 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Indoor Location Market Worth $3.9 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Indoor Location Market Worth $3.9 Billion by 2019 - New Report by MarketsandMarkets 4
... Do adolescents get enough exercise and eat the right ... Researchers analyzed the behavior of almost 900 11-to-15 year-olds ... and dietary risk behaviors, almost half had at least ... of the health guidelines in the study. ...
... the protein EGFR are important for the development of lung ... However, not all individuals// express the same mutant EGFR, for ... of EGFR and some have a mutation that affects the ... ,The potential of therapeutics to benefit individuals with ...
... The most recent Cochrane Review concluded antidepressants bupropion (Zyban) ... smoking and have few side-effects, but selective Serotonin reuptake ... ,Although nicotine medications are known to ... them or wants to use them. One possible alternative ...
... new report finds that less number of women aged 40 ... declining mammography rate could mean more breast cancer deaths down ... rates kept increasing during the 1990s, and scientists are disturbed ... reminded that, despite mammography being a test that's been around ...
... women who take folic acid supplements during their early pregnancy ... baby up to 40%. The Study results were published in ... ,Folic acid, a synthetic compound of a B vitamin ... neural tube disorders such as spina bifida. But its impact ...
... Scientists at UC Irvine have discovered that learning appears to ... hallmarks of Alzheimer's disease.// The finding suggests that the elderly, ... of this degenerative disease. The study appears in the Jan. ... ,This study with genetically modified mice is the first to ...
Cached Medicine News:Health News:Assessing Diet and Exercise Behaviors in Adolescents 2Health News:Mammography Saves Life-Beware Women Over 40 2Health News:Folic Acid Reduces Risk Of Cleft Lip 2Health News:Learning Slows Physical Progression of Alzheimer's Disease: Study 2
... and best value in high performance electronic ... ultra lightweight design reduce hand fatigue and ... lever tip ejector , Color coding for ... or for greater performance use Hamilton AdvanTip ...
... The Research pro Electronic Pipette is ... the laboratory. Its easy-to-follow display, ergonomically-placed operating ... pipetting, dispensing, reverse pipetting and diluting make ... the simple functions of a manual pipette ...
... an Entire Column of a 384 Well Plate ... with 384 well plates, you need a pipettor ... Thats exactly what you get with our 16-channel ... (see Impact/Impact2), this innovation was specifically designed to ...
... a 384 Well Plate at Once , To ... you need a pipettor that can adapt to ... get with our 16-channel Impact pipettor., Available with ... was specifically designed to allow you to transfer ...
Medicine Products: